Literature DB >> 15937753

Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.

Francisco M Marty1, Colleen M Lowry, Martin Rodriguez, Danny A Milner, Walter S Pieciak, Anushua Sinha, Lawrence Fleckenstein, Lindsey R Baden.   

Abstract

There are no parenteral antihelminthic drugs licensed for use in humans. We report the successful treatment of disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin in a patient presenting with severe malabsorption and paralytic ileus. To our knowledge, ivermectin levels are reported for the first time in this situation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15937753     DOI： 10.1086/430827

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  23 in total

1.  Non-oral treatment with ivermectin for disseminated strongyloidiasis.

Authors:  Dahlene N Fusco; Jennifer A Downs; Michael J Satlin; Meera Pahuja; Liz Ramos; Philip S Barie; Lawrence Fleckenstein; Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

Review 2.  The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors:  Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal:  AAPS J       Date:  2008-01-25       Impact factor: 4.009

3.  Failure of ivermectin per rectum to achieve clinically meaningful serum levels in two cases of Strongyloides hyperinfection.

Authors:  Isaac I Bogoch; Kamran Khan; Howard Abrams; Caroline Nott; Elizabeth Leung; Lawrence Fleckenstein; Jay S Keystone
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

Review 4.  Antiparasitic therapy.

Authors:  Shanthi Kappagoda; Upinder Singh; Brian G Blackburn
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

5.  Strongyloides hyperinfection syndrome following resection of meningioma.

Authors:  Clifford Leigh Shelton; Timothy Smith; Konstantina Karabatsou; Katherine Ajdukiewicz
Journal:  BMJ Case Rep       Date:  2012-06-15

6.  A sensitive and selective LC-MS/MS method for quantitation of ivermectin in human, mouse and monkey plasma: clinical validation.

Authors:  Yashpal S Chhonker; Liping Ma; Constant Edi; Daryl J Murry
Journal:  Bioanalysis       Date:  2018-10-16       Impact factor: 2.681

7.  Update on strongyloidiasis in the immunocompromised host.

Authors:  Luis A Marcos; Angélica Terashima; Marco Canales; Eduardo Gotuzzo
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 8.  Human infection with Strongyloides stercoralis and other related Strongyloides species.

Authors:  Thomas B Nutman
Journal:  Parasitology       Date:  2016-05-16       Impact factor: 3.234

Review 9.  Strongyloidiasis in transplant patients.

Authors:  Alison C Roxby; Geoffrey S Gottlieb; Ajit P Limaye
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

10.  Case Report: Ivermectin and Albendazole Plasma Concentrations in a Patient with Disseminated Strongyloidiasis on Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.

Authors:  Carl Boodman; Yashpal S Chhonker; Daryl J Murry; Allison Mah; Jennifer Grant; Theodore Steiner; Michael Libman; Cesilia Nishi; Marthe Charles
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.